(*) USA Approval Date: 2023. 04.03
+enfortumab vedotin-ejfv (2)
>Locally Advanced or Metastatic
Company
Generic Name (1)
RTM (1)
RTM (1) Web-Site
RTM (2)
RTM (2) Web-Site
USA Patent Numbers (1)
USA Patent Numbers (2)